|
| Total (N = 582) | |
|
| First Line Class | Second Line Drugs |
| Monotherapy |
|
|
| Met | 234 (40.2%) | 12 (2.1%) |
| SU | 193 (33.2%) | 11 (1.9%) |
| DPP4 | 4 (0.7%) | 25 (4.3%) |
| Other | 4 (0.7%) | 5 (0.9%) |
| Dual Therapy |
|
|
| Met + SU | 103 (17.7%) | 149 (25.6%) |
| Met + DPP4 | 24 (4.1%) | 160 (27.5%) |
| Met + other | 3 (0.5%) | 10 (1.7%) |
| SU + Thiaz |
| 10 (1.7%) |
| Other Dual therapy | 7 (1.2%) | 32 (5.5%) |
| Triple Therapy |
|
|
| Met + SU + DPP4 | 6 (1.0%) | 85 (14.6%) |
| Met + SU + Thiaz | 3 (0.5%) | 21 (3.6%) |
| Other Triple therapy | 1 (0.2%) | 15 (2.6%) |
| 4 or 4+ Therapy |
| 12 (2.1%) |
| Insulin (May also receive oral therapy) |
| 35 (6.0%) |